Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers

International Journal of Neuropsychopharmacology

Volumn 10, Issue 1, 2007, Pages 41-50

  Blier, Pierre ^a,b,c   Saint André, Élise ^a   Hébert, Chantal ^a,b   De Montigny, Claude ^a   Lavoie, Normand ^a   Debonnel, Guy ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

Antidepressant; Nefazodone; Paroxetine; Reuptake inhibition; Tyramine

Indexed keywords

DESIPRAMINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TYRAMINE; VENLAFAXINE;

ADULT; ARTICLE; ATTENUATION; CONTROLLED STUDY; DEPLETION; DRUG EFFICACY; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VALIDITY;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BLOOD PLATELETS; BLOOD PRESSURE; CYCLOHEXANOLS; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAROXETINE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TRIAZOLES; TYRAMINE;

EID: 33846330588     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006395     Document Type: Article

References (43)

1. Abdelmawla A, Langley R, Szabadi E, Bradshaw C (1999). Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. British Journal of Clinical Pharmacology 48, 345-354.
2. Arora R, Kregel L, Meltzer H (1984). Circadian rhythm of serotonin uptake in the blood platelets of normal controls. Biological Psychiatry 19, 1579-1584.
3. Artigas F, Sarrias MJ, Martinez E, Gelpi E (1985). Serotonin in body fluids: characterization of human plasmatic and cerebrospinal fluid pools by means of a new HPLC method. Life Sciences 37, 441-447.
4. Béïque JC, de Montigny C, Blier P, Debonnel G (1999). Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 32, 198-211.
5. Béïque JC, Lavoie N, de Montigny C, Debonnel G (1998). Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. European Journal of Pharmacology 349, 129-132.
6. Bitsios P, Szabadi E, Bradshaw CM (1999). Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology 143, 286-292.
7. Bolden-Watson C, Richelson E (1993). Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosome. Life Sciences 52, 1023-1029.
8. Debonnel G, Saint-André E, Hébert C, de Montigny C, Lavoie N, Blier P (2006). Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology. doi:10.1017/S1461145705006413.
9. Demet EM, Halaris AE, Bhatarakamol S (1978). Indoleamine compartmentation in human blood. Clinica Chimica Acta 89, 285-292.
10. DeVane CL (1998). Differential pharmacology of newer antidepressants. Journal of Clinical Psychiatry 59 (Suppl. 20), 85-93.
11. Ereshefsky L, Dugan D (2000). Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depression and Anxiety 12 (Suppl. 1), 30-44.
12. Ghose K (1984). Tyramine pressor test: implications and limitations. Methods and Findings in Experimental and Clinical Pharmacology 6, 455-464.
13. Ghose K, Coppen A (1977). Noradrenaline, depressive illness, and the action of amitryptyline. Psychopharmacology (Berlin) 54, 57-60.
14. Ghose K, Turner P (1975). Intravenous tyramine pressor response in depression. Lancet 1, 1317-1318.
15. Gilmor ML, Owens MJ, Nemeroff CB (2002). Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. American Journal of Psychiatry 159, 1702-1710.
16. Gobbi G, Slater S, Boucher N, Debonnel G, Blier P (2003). Neurochemical and psychotropic effects of bupropion in healthy male subjects. Journal of Clinical Psychopharmacology 23, 233-239.
17. Goodman WK, Ward H, Kablinger A, Murphy T (1997). Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Journal of Clinical Psychiatry 58 (Suppl. 5), 32-49.
18. Harvey AT, Rudolph RL, Preskorn SH (2000). Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry 57, 503-509.
19. Hassan SM, Wainscott G, Turner P (1985). A compariso tyramine pressor response test. British Journal of Clinical Pharmacology 19, 705-706.
20. Hassan SM, Wainscott G, Turner P (1989). Paroxetine: lack of effect on the tyramine pressor response in man. ACTA Psychiatrica Scandinavica (Supplementum) 350, 49.
21. Hoffman BB, Lefkowitz RJ (1990). Catecholamines and sympathomimetic Drugs. In: Gilman AG, Rall TW, Nies AS, Taylor P (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics Eighth Edition (pp. 187-220) New York: Macmillan Publishing Co.
22. Hyttel J (1982). Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progress in Neuropsychopharmacology and Biological Psychiatry 6, 277-295.
23. Javors MA, Houston JP, Tekell JL, Brannan SK, Frazer A (2000). Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. International Journal of Neuropsychopharmacology 3, 229-235.
24. Kelsey JE (1996). Dose-response relationship with venlafaxine. Journal of Clinical Psychopharmacology 16, 21S-26S.
25. Kelsey JE (2000). Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. Depression and Anxiety 12 (Suppl. 1), 81-84.
26. Kilts CD, Breese GR, Mailman RB (1981). Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with electrochemical detection. Journal of Chromatography 225, 347-357.
27. Koch DD, Kissinger PT (1980). Current concepts: I. Liquid chromatography with pre-column sample enrichment and electrochemical detection. Regional determination of serotonin and 5-hydroxyindoleacetic acid in brain tissue. Life Sciences 26, 1099-1107.
28. Korpi ER (1984). Serotonin determined in whole blood by liquid chromatography with electrochemical detection. Clinical Chemistry 30, 487-488.
29. Melichar JK, Haida A, Rhodes C, Reynolds AH, Nutt DJ, Malizia AL (2001). Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. Journal of Psychopharmacology 15, 9-12.
30. 11C]DASB positron emission tomography study. American Journal of Psychiatry 161, 826-835.
31. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Journal of Pharmacology and Experimental Therapeutics 283, 1305-1322.
32. Pletscher A (1986). Blood platelets as neuronal models: use and limitations. Clinical Neuropharmacology 9 (Suppl. 4), 344-346.
33. Puozzo C, Leonard BE (1996). Pharmacokinetics of milnacipran in comparison with other antidepressants. International Clinical Psychopharmacology 11 (Suppl. 4), 15-27.
34. Salazar D, Chaikin P, Swanson B, Raymond R (1994). The effects of nefazodone and fluoxetine on platelet serotonin uptake and whole blood serotonin. Clinical Pharmacology & Therapeutics 55, 137-137.
35. Sasa S, Blank CL, Wenke DC, Sczupak CA (1978). Liquid-chromatographic determination of serotonin in serum and plasma. Clinical Chemistry 24, 1509-1514.
36. Seppala T, Linnoila M, Soundergaard I, Elonen E, Mattila MJ (1981). Tyramine pressor test and cardiovascular effects of chlorimipramine and nortriptyline in healthy volunteers. Biological Psychiatry 16, 71-77.
37. Slater S, Gobbi G, Boucher N, Debonnel G, Blier P (2000). Effect of reboxetine on the norepinephrine reuptake processes in healthy male subjects. New Clinical Drug Evaluation Unit 40, 208-208.
38. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology 340, 249-258.
39. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 178, 234-241.
40. Turcotte J, Debonnel G, de Montigny C, Hébert C, Blier P (2001). Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 24, 511-521.
41. Watkins L, Davidson JRT, Connor KM, Beebe KL, Krulewicz S, Abraham K, Zhang W (2003). Effects of paroxetine and venlafaxine-XP on heart rate variability in depression. European Neuropsychopharmacology 13 S274-S274.
42. Wilkins MR, Wynne RD, Kendall MJ (1985). A placebo controlled comparison of the effects of pirenzepine and amitriptyline on the tyramine pressor test in healthy volunteers. British Journal of Clinical Pharmacology 19, 829-831.
43. Zerbe R, Rowe H, Enas G, Wong D, Farid N, Lemberger L (1985). Clinical pharmacology of tomoxetine, a potential antidepressant. Journal of Pharmacology and Experimental Therapeutics 232, 139-143.